LRRC42 Inhibitors
LRRC42 inhibitors are chemical agents that contribute to the reduced functional activity of the protein LRRC42 by interfering with various signaling pathways and proteolytic processes that are essential for its function. Inhibitors such as E-64, ALLN, and Leupeptin target proteolytic enzymes whose activity is critical for the regulation of LRRC42, ensuring that the integrity of protein complexes within LRRC42's pathways is maintained, which in turn leads to the suppression of LRRC42's activity. Similarly, proteasome inhibitors like MG-132 and Lactacystin prevent the degradation of inhibitory proteins within the pathways that LRRC42 is involved in, thereby decreasing LRRC42's functional contribution. Compounds like Pepstatin A and Aprotinin also sustain the levels of negative regulators in these pathways, further diminishing the activity of LRRC42.
Additional mechanisms of LRRC42 inhibition are mediated by chemicals that specifically target signaling kinases. For instance, Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 and LY 294002 work by inhibiting the AKT kinase and PI3K, respectively, both of which are upstream regulators in pathways that govern LRRC42 activity. By blocking AKT, the downstream signaling required for LRRC42 activation is diminished, resulting in reduced activity of LRRC42. Likewise, LY 294002 interferes with the PI3K/AKT pathway, preventing the phosphorylation of key proteins and thereby indirectly suppressing LRRC42 function. Finally, SB 431542, by selectively inhibiting the TGF-β receptor, modifies a critical signaling cascade that indirectly leads to a decrease in LRRC42 activity, further contributing to the collective inhibition of this protein.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $275.00 $928.00 $1543.00 | 14 | |
A cysteine protease inhibitor that can indirectly inhibit LRRC42 by preventing the proteolytic cleavage of proteins within the same pathway in which LRRC42 is involved, thus maintaining the integrity of the pathway's components and diminishing LRRC42's functional activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that can indirectly diminish LRRC42 activity by preventing the degradation of proteins that negatively regulate pathways involving LRRC42, thus maintaining a repressive environment for LRRC42 function. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $72.00 $145.00 $265.00 $489.00 $1399.00 $99.00 | 19 | |
A serine and cysteine protease inhibitor which, by preserving other regulatory proteins within the pathway, can lead to a decrease in LRRC42 functional activity by stabilizing the negative regulatory elements of the pathway. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
A specific proteasome inhibitor that indirectly diminishes LRRC42 activity by stabilizing proteins that act as inhibitors within the pathways LRRC42 is involved in, thus fostering an inhibited state. | ||||||
Aprotinin | 9087-70-1 | sc-3595 sc-3595A sc-3595B | 10 mg 100 mg 1 g | $110.00 $400.00 $1615.00 | 51 | |
A protease inhibitor that, by maintaining the balance of proteolytic activities within the pathway, can lead to decreased LRRC42 activity due to the stabilization of the overall pathway architecture and inhibition of the breakdown of regulatory proteins. | ||||||
Chymostatin | 9076-44-2 | sc-202541 sc-202541A sc-202541B sc-202541C sc-202541D | 5 mg 10 mg 25 mg 50 mg 100 mg | $153.00 $255.00 $627.00 $1163.00 $2225.00 | 3 | |
A chymotrypsin-like protease inhibitor that indirectly inhibits LRRC42 by maintaining the presence of its negative regulators within the pathway, thus creating an inhibitory effect on LRRC42 function. | ||||||
PD 150606 | 179528-45-1 | sc-222133 sc-222133A | 5 mg 25 mg | $116.00 $395.00 | 18 | |
A calpain inhibitor that indirectly inhibits LRRC42 by stabilizing the proteins within the pathway that LRRC42 interacts with, leading to diminished LRRC42 activity due to the maintained presence of inhibitory signals. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $204.00 $265.00 | 29 | |
A specific inhibitor of AKT, a kinase that participates in signaling pathways involving LRRC42. By inhibiting AKT, the downstream signaling that leads to the activation of LRRC42 is diminished, resulting in decreased LRRC42 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that indirectly diminishes LRRC42 activity by preventing the phosphorylation and activation of downstream proteins within the PI3K/AKT pathway, which is essential for the functional activity of LRRC42. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
A selective inhibitor of the TGF-β receptor, which indirectly leads to the decreased activity of LRRC42 by altering the TGF-β signaling pathway that is known to modulate the function of proteins like LRRC42. | ||||||